The current diagnosis of DIIHA relies mainly on laboratory tests, with patients typically presenting hemolytic manifestations such as decreased hemoglobin levels and hyperbilirubinemia, along with positive direct anti-human globulin tests (DAT) for anti-C3 and/or IgG/IgM (Arndt, 2014; Salama and Mayer, 2014). Here, C3 is linked to Hyperbilirubinemia.